IDTF USA Patients monitoring 1-30 days. Potentially years for chronic care services. Medicare rebates are expected during 2019.
Nasdaq Listing US prospectus public in coming weeks e.g. May 2019.
HKSE Listing Anticipated within 3rd Quarter 2019 e.g. Sept 2019
UK G Medical Patch completed pilot program and is now moving to expanding the programs as well as commercializing multiple accounts with its afficiates.
Yacov Geva Loan Agreement The board of directors thanks Dr Geva and this exemplifies the continued support and faith the CEO has in the future of the company. The conversion of the portion of the loan into shares is anticipated shortly.
Board appointment World renowned Cardiologist Professor Zeev Rothstein to the Board of Directors.
CFDA Granted Green Channel Prizma Additional work is currently being finalised to be finalized in May 2019 and will form part of final regulatory documentation. G Medical Patch is in progress with regulatory process.
DYOR.
My opinion: CFDA GM Patch could be approved by June 2019. CFDA Prizma could be approved by July 2019. Nasdaq Listing could be July 2019
02 Nov 2018 update The Telerhythmics acquisition will substantially increase insurance coverage and create a distinct competitive advantage providing G Medical 100 commercial payor across national markets and additional 30-35 million covered lives. With the company's aggregated sum increasing to 100 million lives. G Medical will also gain access to several large health systems and large urance providers.
Its appears G Medical will do Nasdaq Listing with or without CFDA as they are confident with IDTF (Independent Diagnostic Testing Facility)
I am very happy with my own research. Looking forward for GMV this year.
GMV Price at posting:
27.0¢ Sentiment: Buy Disclosure: Held